Phase IBII Study of Targeted Treatments and Immunotherapy With Atezolizumab for Women With Recurrent or Persistent Endometrial Cancer
Led by Alliance Foundation Trials, LLC. · Updated on 2026-04-01
148
Participants Needed
21
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of targeted treatments, with or without the immune therapy drug atezolizumab, in women with recurrent or persistent endometrial cancer. This Phase IBII study uses genetic testing of tumor samples to assign participants to different groups based on specific tumor markers. The study aims to better understand how these targeted agents work in combination with or without immunotherapy and to identify the best treatment options for specific tumor profiles.
Participants will first provide tumor tissue for genomic testing using the FoundationOne companion diagnostic. Based on the tumors genetic features, participants will be placed into specific study groups receiving targeted drugs alone or combined with atezolizumab. Treatments include various intravenous and oral drugs administered in cycles of 21 or 28 days. Each group enrolls about 20 to 24 participants and can be closed or expanded depending on results. The study also allows for additional groups to be added over time.
During the study, participants will receive regular treatments and be monitored for tumor response, survival, and disease progression over several months. Researchers will assess overall response rates and the duration participants remain free from disease progression. Safety and side effects will also be closely monitored. Participants may have tumor scans, blood tests, and other evaluations to track the study drugs effects. The total follow-up period for outcomes like survival is up to 48 months, ensuring long-term observation of treatment impact.
CONDITIONS
Brief Title
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Research Team
Q
Quality Management and Compliance
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Atezolizumab + Talazoparib Cohort
Inavolisib + Letrozole Cohort
Giredestrant + Abemaciclib Cohort
Current Standard Systemic Therapy
What it is
Combination of atezolizumab (immunotherapy) and talazoparib (PARP inhibitor) for patients with recurrent or persistent endometrial carcinoma.
Combination of inavolisib (PI3K inhibitor) and letrozole (hormonal therapy) for women with recurrent or persistent endometrial carcinoma.
Combination of giredestrant (estrogen receptor degrader) and abemaciclib (CDK4/6 inhibitor) for recurrent or persistent endometrial carcinoma.
Current systemic therapy, such as chemotherapy (including agents like doxorubicin or carboplatin-paclitaxel) or hormone therapy, offered to patients with previously treated recurrent endometrial cancer.
Primary use
Designed to evaluate if immunotherapy plus PARP inhibition improves response rates or disease control in patients with recurrent endometrial cancer.
Aims to determine whether combining PI3K inhibition with hormonal therapy enhances clinical outcome in patients with recurrent endometrial carcinoma.
Evaluates the effect of combining estrogen receptor targeting and CDK4/6 inhibition on disease progression and response in endometrial cancer.
Used for disease control, symptom management, and overall survival benefit in the recurrent/persistent endometrial cancer population.
Evidence status
Clinical efficacy in recurrent endometrial cancer for this combination is still under investigation, with no published outcome data yet.
Efficacy and response rates for this investigational combination remain unreported and are currently being studied.
Data regarding disease control or response rate for the giredestrant and abemaciclib combination in endometrial cancer are not yet established.
Chemotherapy and hormone therapy have established roles in recurrent endometrial cancer, with documented efficacy in disease control and progression-free survival, though durable responses are limited.
Important limitations
The combination regimen’s benefit in endometrial carcinoma is unproven and specific risks or safety profile in this population are not yet fully described. Biomarker-driven eligibility may also restrict access.
Potential adverse effects and unknown efficacy for this PI3K inhibitor/hormone therapy combination in endometrial cancer. Cohort assignment may depend on biomarker profile, and clinical outcomes are pending.
Risks, tolerability, and effectiveness of combining an estrogen receptor degrader with a CDK4/6 inhibitor in endometrial cancer have not been established and depend on trial results.
Chemotherapy and hormone therapy are limited by modest response rates and lack of durable benefit in advanced recurrent endometrial cancer. Toxicity and resistance may further restrict options.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
FEMALE
Eligibility Criteria
You may qualify if you...
Female participants aged 18 years or older
Diagnosis of recurrent or persistent endometrial carcinoma progressed after 1 to 2 prior lines of therapy
Measurable disease according to RECIST 1.1 criteria
Availability of tumor tissue suitable for biomarker testing via FoundationOne companion diagnostic or recent equivalent test
Life expectancy greater than 12 weeks
Recovery from effects of recent radiotherapy, surgery, or chemotherapy
You will not qualify if you...
Endometrial tumors with squamous carcinomas or sarcomas histologies
Invasive malignancies within the last 5 years, except certain skin and breast cancers
Synchronous primary invasive ovarian or cervical cancer
Active or history of autoimmune disease or immune deficiency
History or evidence of lung diseases including pneumonitis or pulmonary fibrosis
Active tuberculosis or severe infections within 4 weeks
Recent therapeutic antibiotic use within 2 weeks, except prophylactic use
Significant cardiovascular disease
Treatment with live attenuated vaccines within 4 weeks or planned during study
Prior allogeneic bone marrow or solid organ transplant
Recent treatment with systemic immunostimulatory or immunosuppressive agents
Untreated central nervous system disease, uncontrolled seizures, or recent cerebrovascular events
Prior treatment with certain immune checkpoint therapies for specific cohorts (AFT-50A)
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Repeated 28-day cycles until disease progression or discontinuation
Participants receive targeted drug therapies based on their tumor's genomic profile. Treatment involves cycles of intravenous and oral medications administered according to their assigned cohort.
1 visit per cycle (in-person) for drug administration and monitoring
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
7
Similar Trials
Safety and Dosimetry Study of 177Lu-RAD204 Targeting PD-L1 in Patients With Selected Metastatic Solid Tumors
Study of 177LuBetaBart Monoclonal Antibody for Safety and Early Effects in Adults With Advanced Solid Tumors
Evaluating 18F-T2 PETCT Imaging for Detecting Tumors with High CAIX Levels in Adults
Study of Using 3D-Printed Custom Devices for High-Dose Radiation Treatment in Gynaecological Cancer
Phase III Trial Comparing BNT323 Versus Chemotherapy for HER2-Positive Recurrent Endometrial Cancer
Study on Cervical and Endometrial Cancer in Women Aged 20 to 75
Open-Label Phase 1 Trial Evaluating Safety and Activity of HH160 Alone or With Other Cancer Treatments in Adults With Advanced or Metastatic Solid Tumors
Study of CTIM-76, a Claudin-6 Directed Bispecific Antibody, in Adults With Platinum-Resistant Ovarian Cancer and Advanced Solid Tumors
Phase 1 Open-label Study of LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, Given Intravenously in Advanced Solid Tumors to Determine Safety and Recommended Dose
Phase 1a1b Study of NRM-823 Alone and With Immune Checkpoint Inhibitor in Advanced or Metastatic Refractory Solid Tumors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Jonathan E Rosenberg, Jean Hoffman-Censits, Tom Powles...
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
Correction: A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Kyle C Strickland, Brooke E Howitt, Sachet A Shukla...